In summary, we presented a case of an elderly man with statin-naive immune-mediated necrotizing myopathy positive for both anti-HMGCR and anti-SRP autoantibodies. Anti-HMGCR antibody-positive immune-mediated necrotizing myopathy may be associated with exposure to naturally occurring dietary HMGCR inhibitors as well as statins. For successful treatment of anti-HMGCR immune-mediated necrotizing myopathy, both cessation of the offending agent and treatment with glucocorticoids and immunosuppression are often necessary.
You Might Also Like
Explore This IssueApril 2019
Physicians need to consider not only the patient’s medical and social history, but also their dietary history when evaluating patients suspected to have immune-mediated necrotizing myopathy.
Takeshi Yoshida, MD, Hiroaki Chikazawa, MD, and Yoshitaka Kumon, MD, PhD, all work in the Department of Rheumatology at Chikamori Hospital, Kochi, Japan.
Ichizo Nishino, MD, PhD, is the director of the Department of Neuromuscular Research at the National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Call for Cases
The 2019 Thieves Market Call for Cases is now open. Find more information on the ACR website.
This study was supported in part by Intramural Research Grant (29-4) for Neurological and Psychiatric Disorders from the National Center of Neurology and Psychiatry.
- Stenzel W, Goebel HH, Aronica E. Review: Immune-mediated necrotizing myopathies—a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol. 2012 Dec;38(7):632–646.
- Mammen AL. Statin-associated autoimmune myopathy. New Engl J Med. 2016 Feb 18;374(7):664–669.
- Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011 Mar;63(3):713–721.
- Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1038–1044.
- Klein M, Mann H, Pleštilová L, et al. Increasing incidence of immune-mediated necrotizing myopathy: Single-centre experience. Rheumatology (Oxford). 2015 Nov;54(11):2010–2014.
- Liang WC, Uruha A, Suzuki S, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology (Oxford). 2017 Feb;56(2):287–293.
- Selva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, et al. Statin-induced myalgia and myositis: An update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018 Mar;14(3): 215–224.
- Ohnuki Y, Suzuki S, Shiina T, et al. HLA-DRB1 alleles in immune-mediated necrotizing myopathy. Neurology. 2016 Nov 1;87(18):1954–1955.
- Gil-Ramírez A, Clavijo C, Palanisamy M, et al. Screening of edible mushrooms and extraction by pressurized water (PWE) of 3-hydroxy-3-methyl-glutaryl CoA reductase inhibitors. J Funct Foods. 2013 Jan;5(1):244–250.
- Gil-Ramírez A, Caz V, Smiderle FR, et al. Water-soluble compounds from Lentinula edodes influencing the HMG-CoA reductase activity and the expression of genes involved in the cholesterol metabolism. J Agric Food Chem. 2016 Mar 9;64(9):1910–1920.
- Ikemoto K, Suzuki S, Uruha A, et al. Enzyme-linked immunosorbent assays for diagnosis of immune-mediated necrotizing myopathy. Clin Exp Neuroimmunol. 2016 Aug;7(3):291–293.